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27 Antimicrobial resistance (AMR) is commonly found in Clostridium difficile strains and plays 
28 a major role in strain evolution. We have previously reported the isolation of large clostridial 
29 toxin-negative, binary toxin-producing (A-B-CDT+) C. difficile strains from colonised (in 
30 some instances diarrhoeic) food animals, as well as from patients with diarrhoea. To further 
31 characterise these strains, we investigated the phenotypic and genotypic AMR profiles of a 
32 diverse collection of A-B-CDT+ C. difficile strains. The in vitro activities of 10 antimicrobial 
33 agents were determined for 148 A-B-CDT+ C. difficile strains using an agar dilution 
34 methodology. Whole-genome sequencing and in silico genotyping was performed on 53 
35 isolates to identify AMR genes. All strains were susceptible to vancomycin, metronidazole 
36 and fidaxomicin, antimicrobials currently considered first-line treatments for C. difficile 
37 infection (CDI). Differences in antimicrobial phenotypes between PCR ribotypes (RTs) were 
38 observed but were minimal. Phenotypic resistance was observed in 13 isolates to tetracycline 
39 (TetR, MIC=16 mg/L), moxifloxacin (MxfR, MIC=16 mg/L), erythromycin (EryR, MIC 
40 ≥128 mg/L) and clindamycin (CliR, MIC=8 mg/L). The MxfR strain (RT033) possessed 
41 mutations in gyrA/B, while the TetR (RT033) strain contained a tetM gene carried on the 
42 conjugative transposon Tn6190. All EryR and CliR strains (RT033, QX521) were negative 
43 for the erythromycin ribosomal methylase gene ermB, suggesting a possible alternative 
44 mechanism of resistance. This work describes the presence of multiple AMR genes in A-B-
45 CDT+ C. difficile strains and provides the first comprehensive analysis of the AMR repertoire 




48 Clostridium difficile is a Gram-positive obligately anaerobic bacillus that can persist under 
49 aerobic conditions in a non-vegetative spore form. C. difficile infection (CDI) is the leading 
50 cause of antimicrobial-associated diarrhoea in most developed countries with high rates of 
51 healthcare-related infections reported, especially in European and North American hospitals 
52 (1). The prevalence of CDI has increased in parallel with the greater use of antimicrobials, 
53 most nptably clindamycin, cephalosporins and fluoroquinolones (2-4). Antimicrobial 
54 treatment destroys the commensal gut bacteria that contribute to the inhibition of C. difficile 
55 spore outgrowth, creating an imbalance (5). A continual dysbiosis is exploited by C. difficile 
56 resulting in CDI recurrences that have become a substantial strain on health care systems in 
57 regions with high incidences of CDI (6).
58 In the early 2000s, a new generation quinolone (fluoroquinolone) resistant strain of C. 
59 difficile, RT027/NAP1/B1, caused outbreaks of CDI in Europe and North America leading to 
60 the implementation of antimicrobial stewardship policies in hospital settings in these regions 
61 (7). Today, although infections due to C. difficile RT027 have decreased, fluoroquinolone 
62 resistance continues to promote the spread of other C. difficile RTs. In particular, 
63 moxifloxacin resistance is commonly found in C. difficile RTs, an indication of the need for 
64 frequent review and audit of antimicrobial stewardship policies (8). 
65 Oral vancomycin and metronidazole are the preferred therapeutic options for mild or 
66 moderate CDI while a combination of oral metronidazole and intravenous vancomycin is 
67 recommended for severe disease (9). Both antimicrobials have been linked to disease 
68 recurrences due to the spore-forming nature of C. difficile, which is resistant to these 
69 treatments (9). Fidaxomicin, a narrow-spectrum, sporicidal macrolide that is highly effective 
70 against C. difficile, is occasionally used as a first-line therapy due to its microbiota preserving 
ACCEPTED MANUSCRIPT
4
71 property that greatly reduces the probability of recurrent CDI (10, 11). Despite it’s proven 
72 effectiveness, the cost of fidaxomicin is substantially higher than other therapies and, coupled 
73 with the substantial healthcare costs of CDI, it is not affordable in many parts of the world 
74 (12). In the US, a region highly impacted with CDI, a case of recurrent CDI costs up to 
75 $18,000 (12).
76 Currently, there is global widespread use of antimicrobials in both hospital and community 
77 settings. Approximately 5 out of 6 individuals in the US receive a course of antibiotics 
78 annually (13). As a result, increased antimicrobial resistance (AMR) and reduced 
79 susceptibilities to multiple antimicrobials has become common (1, 14). On the other hand, the 
80 use of alternate CDI therapies such as faecal microbiota transplantation and microbial 
81 ecosystem therapeutics is becoming popular due to excellent recovery rates for recurrent 
82 infections and the lack of dependency on antimicrobials (15). However, these carry the risk 
83 of acquiring AMR genes from donors (1, 15). These concerns emphasize the importance of 
84 AMR surveillance in both large clostridial toxin-positive (toxigenic) and large clostridial 
85 toxin-negative C. difficile strains. 
86 Antimicrobial susceptibility patterns of toxigenic C. difficile strains have been determined 
87 periodically while large clostridial toxin-negative C. difficile strains have been ignored. Large 
88 clostridial toxin-negative C. difficile strains lack the main virulence factors (toxins A and B), 
89 however, they may encode a third binary toxin (CDT), the significance of which is not well 
90 understood despite it being associated with more severe disease (16,17).  CDT shares 80%-
91 85% homology with iota toxin (ɩ-toxin) produced by C. perfringens type E and also possesses 
92 an ADP-ribosyltransferase activity that modifies actin in the host cells leading to its de-
93 polymerization and inability to form filaments, eventually resulting in destruction of the cell 
94 cytoskeleton (17).  In vitro experiments have confirmed toxicity of CDT and its crucial role 
95 in adherence and colonisation (17). Recently, C. difficile strains producing only CDT (A-B-
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96 CDT+) have been isolated from diarrhoeic individuals with recurrent CDI symptoms 
97 suggesting the possibility of CDI in the absence of toxigenic C. difficile strains (18).
98 Although the role of CDT in infection is unclear, we postulated that A-B-CDT+ C. difficile 
99 strains may harbour other non-toxin virulent factors, including antimicrobial resistance, that 
100 contribute to their ability proliferate and cause symptoms in infected patients.  The purpose of 
101 this study was to determine the antimicrobial susceptibilities of a collection of A-B-CDT+ C. 
102 difficile strains to a range of antimicrobial agents. In addition, a selection of the strains was 
103 whole-genome sequenced to corroborate the phenotypic results.
104 Materials and methods
105 Bacterial isolates
106 C. difficile isolates were selected based upon genetic uniqueness using previous molecular 
107 analysis of PCR ribotypes (RTs), toxin gene profiles and multilocus sequence types (MLST, 
108 STs). The strains belonged to ten RTs (033, 238, 239, 288, 585, 586, QX143, QX360, 
109 QX444, QX521) and were collected from diverse sources (human faeces, n=28; foal, n=1; 
110 calves, n=52; pigs, n=40; food, n=1; effluent, n=26). Table 1 illustrates the various RTs, 
111 sequence types (STs) and general characteristics of the isolates analysed. 
112 Bacterial culture
113 C. difficile isolates previously frozen at -80°C using brain heart infusion broth (supplemented 
114 with 15% glycerol) were revived on blood agar (BA) plates. BA plates were incubated 
115 anaerobically (A35 Anaerobic Workstation, Don Whitley Scientific, Shipley, West Yorkshire 
116 BD17 7SE, United Kingdom) for 48 h to obtain pure cultures. C. difficile colonies were 




119 The minimum inhibitory concentrations (MICs) of pure C. difficile isolates were determined 
120 using a CLSI-recommended agar dilution method as previously described (19). A total of 148 
121 A-B-CDT+ C. difficile isolates were tested against 10 antimicrobials consisting of current CDI 
122 therapies (vancomycin, metronidazole, fidaxomicin and rifaximin), antimicrobials associated 
123 with high resistance and risk of CDI development (moxifloxacin, erythromycin, clindamycin) 
124 and broad-spectrum antimicrobials frequently that may lead to CDI (meropenem, 
125 amoxicillin/clavulanate and tetracycline). The MICs were interpreted using CLSI and 
126 EUCAST guidelines where available (20, 21). For fidaxomicin and rifaximin, a European 
127 Medical Agency proposed breakpoint of 1.0 mg/L (report WC500119707, 
128 http://www.ema.europa.eu/) and recommended breakpoint of ≥32 mg/L (22) were used, 
129 respectively.
130 DNA sequencing, genome assembly and data analysis
131 Whole-genome sequencing (WGS) of 53 C. difficile isolates representative of the 148 A-B-
132 CDT+ isolates was performed using methods described by Knight et al. (23).  Bacterial DNA 
133 libraries were generated using standard Nextera XT protocols (Illumina® Inc., San Diego, 
134 CA, USA) and paired-end (PE) sequencing was performed on the Illumina® Miseq Platform. 
135 Quality control and bioinformatic processing of raw reads were performed as described by 
136 Knight et al. (24). AMR genes and STs were detected in silico using the ARG-ANNOT and 
137 PubMLST databases, respectively, compiled in the short-read typing algorithm SRST2 v0.1.8 
138 (23-25). Draft genomes were assembled and annotated as previously described (23). Manual 
139 investigation of acquired and intrinsic resistance loci and their underlying genomic context 
140 was performed using a custom sequence library comprising mobile genetic elements 




143 All isolates were susceptible to fidaxomicin, rifaximin, vancomycin, metronidazole, 
144 amoxicillin/clavulanate and meropenem (Table 2). Phenotypic resistance was observed in 
145 9.3% (3/28) of human isolates, 38.5% (10/26) of effluent isolates and 0% of cattle (0/53) and 
146 pig (0/40) isolates. A total of 13/148 C. difficile isolates from humans (n=3) and effluent 
147 (n=10) exhibited phenotypic resistance to tetracycline (TetR, MIC=16mg/L), moxifloxacin 
148 (MxfR, MIC=16mg/L), erythromycin (EryR, MIC ≥128mg/L) and clindamycin (CliR, 
149 MIC=8mg/L). All cattle and pig C. difficile isolates were susceptible to all antimicrobial 
150 agents tested. In total, 10 different RTs were analysed and the resistant isolates belonged to 
151 two RTs only, RTs 033 (n=11, 84.6%) and QX521 (n=2, 15.4%).  
152 Non-synonymous mutations in the DNA gyrase GyrA/B were detected in the MxfR isolate 
153 (RT033) with distinct allele types (GyrA [Lys413Asn], GyrB [Gln160His, Ser366Val, 
154 Ser416Ala, Asp426Asn]). The Asp426Asn and Ser416Ala mutations in GyrB correlated with 
155 fluoroquinolone resistance and the other mutations were non-synonymous mutations that fell 
156 outside the quinolone resistance-determining regions (QRDR) of GyrA and B. The TetR 
157 strain, also belonging to RT033, contained a tetM gene (encoding a ribosomal protective 
158 protein) carried on a conjugative transposon Tn6190, originally discovered in the M120 strain 
159 of RT078 (accession NC_017174) isolated from an Irish diabetic patient (Table 3). No EryR 
160 or CliR strain contained methylase erm genes, suggesting a possible alternative mechanism of 
161 resistance in these strains. 
162 Eight RT033 isolates also possessed aminoglycoside resistance genes (aph3-III and sat4A) 
163 and harboured a 7269bp fragment of a multidrug resistance gene cassette from the ruminant 
164 facultative anaerobe Erysipelothrix rhusiopathiae (99% nucleotide seq ID to KP339868.1). 
165 Interestingly, this cassette also had a third (syntenic) aminoglycoside gene (ant6-Ia), which 
ACCEPTED MANUSCRIPT
8
166 was not picked up by SRST2 analysis but identified on manual curation of the assembled 
167 genome. Further manual curation of the A-B-CDT+ C. difficile genomes detected genes 
168 encoding a β-lactamase inducing penicillin-binding protein (blaR) and a multidrug resistance 
169 transporter protein (cme), loci that have been reported previously in other C. difficile lineages 
170 (Table 3).
171 Discussion 
172 This work illustrates antimicrobial phenotypic resistance and the presence of multiple AMR 
173 genes in A-B-CDT+ C. difficile RTs isolated from human, animal and environmental (effluent) 
174 sources.  Our collection of C. difficile RT033 strains exhibited resistance to more 
175 antimicrobials of different classes than any other A-B-CDT+ C. difficile RT tested. This is 
176 noteworthy because this RT, despite being thought of as not clinically relevant, has been 
177 associated with human infections in Australia, Europe and North America (18, 26-28). We 
178 hypothesize that the presence of multiple AMR genes in this RT may be a factor driving the 
179 increased incidence of RT033 human and animal infections. 
180 C. difficile RT033, also classified as toxinotype XI, is common in food animals, especially 
181 piglets and veal calves (29). It belongs to ST11 and MLST clade 5, a clade known to cause 
182 significant mortality that contains the so-called “hypervirulent” RT078 strain (22). 
183 Symptomatic human cases of RT033 infection described in the literature include single cases 
184 from Australia, Italy and North America, and four cases from France (18, 26-28). We 
185 recently reported the discovery of a vanB2-like vancomycin resistance operon from an 
186 RT033 C. difficile strain isolated from an Australian veal calf at slaughter (31). Although 
187 phenotypically inactive, possibly due to fragmentation in the vanRB gene, the origin of this 
188 element in vancomycin-resistant Enterococcus species illustrates the possibility that a fully 
189 vancomycin-resistant strain of C. difficile may emerge. None of our RT033 C. difficile 
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190 isolates contained a vanB2 operon and they were all susceptible to vancomycin (MIC=1-2 
191 mg/L, Table 2). However, they showed similar phenotypic resistance characteristics to 
192 clinically relevant toxigenic C. difficile strains.
193 Since the initial association between CDI and antimicrobial therapy was confirmed, many 
194 toxigenic C. difficile strains have been reported as resistant to clindamycin and erythromycin, 
195 often related to the rRNA adenine N-6-methyltransferase encoded by the ermB gene (32,33). 
196 Approximately 17 mobile elements have been linked to macrolide-lincosamide-streptogramin 
197 B (MLSB) resistance in C. difficile but Tn5398 is the most commonly identified ermB-
198 containing element found in CliR and EryR C. difficile strains (1).  Notably, this non-
199 conjugative element contains two copies of ermB genes (1). Some of our A-B-CDT+ C. 
200 difficile RTs (033, n=8 and QX521, n=2) displayed an MLSB phenotype yet did not harbour 
201 any of the known methylase subclasses (ermB, ermC or ermTR). This discordance has been 
202 observed in C. difficile previously, and publications have suggested that mutations in L4/L22 
203 riboproteins and 23s rRNA could explain the MLSB resistance (1). Analysis of the sequenced 
204 genomes showed that both the L4/L22 riboprotein genes and 23s rRNA genes in this 
205 population were full-length and wildtype with no variations identified that were found 
206 exclusively in MLSB+ strains. However, analysis of the multiple 23s rRNA alleles present in 
207 a typical C. difficile genome was not possible with the Illumina short-read sequencing 
208 approach used in this study.
209 Fluoroquinolone resistance (FQR) in C. difficile has been continually documented since the 
210 outbreaks caused by two independently evolved FQR lineages of C. difficile RT027/BI/NAP1 
211 in Canada, USA and Europe between 2002 and 2006 (1, 23). Although the incidence of C. 
212 difficile RT027 infections has markedly reduced in some countries, FQR in other C. difficile 
213 RTs continues to emerge, most notably in ST11 and RT017 lineages (23). Mutations within 
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214 the defined QRDRs of DNA gyrase subunits GyrA and/or GyrB generally confer resistance 
215 to FQs, however, non-QRDR polymorphisms resulting in FQR have been observed (33). We 
216 identified both QRDR and non-QRDR mutations in gyrA/B. These mutations were identified 
217 in an isolate (RT033) that was phenotypically resistant to moxifloxacin (MIC=16mg/L). The 
218 isolate originated from a patient in France who was considered to have CDI and had only A-
219 B-CDT+ C. difficile RT033 isolated from stool specimens. The patient fully recovered after 
220 treatment with oral metronidazole, however, this case exemplifies acquisition and possible 
221 proliferation of the FQR genotypes within A-B-CDT+ C. difficile strains (18).
222 With regard to tetracycline, resistance in C. difficile is thought to be less common and varies 
223 between countries and RTs (34). C. difficile tetracycline resistance genes are commonly 
224 carried on Tn916 and Tn5397-like mobile elements, however, mobile elements that carry 
225 TetR genes from other bacterial species have been identified in C. difficile e.g. tetA/B (23). 
226 The TetR strain in our A-B-CDT+ C. difficile collection, also an RT033 strain, contained 
227 a tetM gene carried on a conjugative transposon Tn6190, originally discovered in C. difficile 
228 RT078 strain M120 and, to date, only reported in C. difficile ST11 lineages RT126 and 
229 RT078 (35). Tn6190 is 97% homologous to Tn916 and considered to circulate in pigs (36). 
230 Our TetR isolate originated from a patient with idiopathic diarrhoea suggesting possible 
231 zoonotic transmission, although a higher-resolution typing approach such as core genome 
232 SNP analysis would be needed to confirm this (35).
233 In Australia and The Netherlands, bi-directional transmission (zoonotic and anthroponotic) of 
234 C. difficile has been demonstrated that may be facilitating dissemination of AMR genes (23, 
235 37). However, in this study, we observe the possible multi-directional transmission of AMR 
236 genes from human, animal and effluent sources. Ten of 13 resistant isolates (76.9%) came 
237 from an environmental source (effluent from a piggery) and indicated phenotypic resistance 
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238 to erythromycin (≥128mg/L). These isolates belonged to RTs 033 and QX521 (novel 
239 ribotype). We did not isolate QX521 from any other source, however, C. difficile RT033 was 
240 detected from all the sources (human, animal, food and effluent) and at least one RT033 
241 isolate from each source (besides food) contained AMR genes (Table 3). Additionally, the 
242 RT033 isolates from human and effluent sources exhibited multi-drug resistant (MDR) 
243 phenotypes (resistance to two or more antimicrobials) to moxifloxacin, clindamycin, 
244 erythromycin and tetracycline. These results emphasize the importance of a ‘One Health’ 
245 approach to combating AMR in C. difficile (38).
246 While considerable effort is being made in directing antimicrobial stewardship, there is 
247 increasing concern about the development of resistance to clinically consequential 
248 antimicrobials. In this study, we successfully demonstrated that A-B-CDT+ C. difficile strains 
249 from diverse sources are reservoirs of AMR genes that have also been identified in clinically 
250 relevant toxigenic C. difficile strains. 
251 Conclusion
252 AMR is a One Health issue that highlights the importance of the association between human 
253 health, animal health and the environment. While the role of A-B-CDT+ C. difficile strains in 
254 idiopathic diarrhoea is still unclear, these strains remain common in food animals and could 
255 potentially transmit AMR genes. In the future, we will further investigate the evolution and 
256 transmission of these strains using high-resolution core genome phylogenetics. However, the 
257 present study provides a basis for this with a comprehensive analysis of AMR profiles of 
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385 Table 1. Distribution of PCR ribotypes and sequence types (STs) of the various A-B-CDT+ C. difficile isolates (n=148) included in the study.
C. difficile MLST genes





RT 238 5 8 5 26 15 29 8 169 5 Pigs Australia, n=23 NI1
QX 143 5 8 5 28 15 28 59 386 5 Human Australia, n=1 Symptomatic
RT 585 5 15 5 27 15 29 20 164 5 Human Australia, n=4 Symptomatic
Foal Australia, n=1 Symptomatic
RT 239 10 8 19 11 15 29 22 168 5 Human Australia, n=2 Symptomatic
RT 033 5 8 8 11 9 11 8 11 5 Human Australia, n=11 Symptomatic
Human France, n=6 Symptomatic
Pigs Australia, n=17 NI
Food Australia, n=1 NA2
Effluent Australia, n=10 NA
Calves Australia, n=24 Asymptomatic
RT 586 5 8 5 27 15 29 22 167 5 Human Australia, n=1 Symptomatic
RT 288 5 8 5 11 9 11 8 11 5 Calves Australia, n=28 NI
Human Australia, n=1 Symptomatic
QX 444 5 8 5 26 15 29 8 169 5 Human Australia, n=1 Symptomatic
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QX 521 5 8 5 27 15 28 8 280 5 Effluent Australia, n=16 NA
QX 629 5 8 5 27 15 29 8 315 5 Human Australia, n=1 Symptomatic
386
387
388 All isolates belonged to the evolutionary divergent lineage clade 5 and were distributed within eight STs. MLST- Multi-Locus Sequence Type. 
389
Table 2: Susceptibility of A-B-CDT+ C. difficile strains to 10 antimicrobial agents.
Sources






























aVAN  1 - 2 1/1 1 1/1 1 1/1 1 - 2 1/1 1 1/1 1 - 2 1/1 100/-/0
aMTZ  0.25 – 0.5 0.5/0.5 0.5 0.5/0.5 0.12 – 0.5 0.5/0.5 0.25 - 1 0.25/0.5 0.12 – 0.5 0.25/0.5 0.12 - 1 0.5/1 100/-/0
bFDX  0.004 – 0.12 0.03/0.06 0.015 0.015/0.015 0.004 – 0.06 0.015/0.06 0.004 – 0.06 0.03/0.03 0.008 – 0.12 0.03/0.06 0.004 – 0.12 0.03/0.12 100/-/0
cMXF  1 - 16 1/1 1 1/1 1 - 2 1/1 1 - 2 1/2 1 - 4 1/2 1 - 2 1/1 98.6/0.7/0.7
cCLI   0.12 - 8 0.5/4 0.5 0.5/0.5 0.12 - 4 1/4 0.03 - 4 0.5/1 0.03 - 8 1/4 0.03-8 0.5/4 92.6/6.7/0.7
cERY  0.12 - 128 1/1 0.5 0.5/0.5 0.25 - 4 0.5/0.5 0.5 - 4 1/1 0.25 - 128 8/128 0.12 - 128 1/4 -/-/6.7
cMER  1 - 4 2/2 2 2/2 2 2/2 2 - 4 2/4 2 - 4 2/2 2 - 4 2/2 100/0/0
cAUG  0.25 - 1 0.5/1 0.5 0.5/0.5 0.25 – 0.5 0.5/0.5 0.25 - 2 0.5/0.5 0.25 – 0.5 0.5/0.5 0.25 -2 0.5/1 100/0/0
dRFX  0.004 - 2 0.008/0.008 0.008 0.008/0.008 0.004 0.004/0.004 0.004 - 1 0.008/0.008 0.004 – 0.015 0.008/0.008 0.004 - 2 0.004/0.015 100/-/0
cTET  0.03 – 0.25 0.12/0.25 0.12 0.12/0.12 0.06 – 0.12 0.12/0.12 0.06 - 8 0.12/2 0.06 – 0.12 0.06/0.12 0.06 - 8 0.12/2 98.0/1.3/0.7
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390 S- susceptible, I-intermediate, R- resistant. Breakpoints (minimum inhibitory concentration [mg/L]; S, I, R) for each antibiotic were as follows: VAN- 
391 Vancomycin (≤2/-/˃2), MET- Metranidazole (≤2/-/˃2), FDX- Fidaxomicin (-/-/≥1), MXF- Moxifloxacin (≤2/4/≥8), CLI- Clindamycin (≤2/4/≥8), ERY- 
392 Erythromycin (-/-/˃8), MER-Meropenem (≤4/8/≥16), AUG- Amoxicillin/clavulanate (≤4/8/≥16), RFX- Rifaximin (-/-/≥32), TET- Tetracyline (≤4/8/≥16). 
393 aEUCAST breakpoints (21).  bResistance (≥1.0 mg/L) as described by European Medical Agency (report WC500119707, http://www.ema.europa.eu/).  





Table 3. AMR genes detected from raw sequence reads of A-B-CDT+ C. difficile 
strains, n=53.
Phenotype Gene(s) Ribotype Toxin profile Source
Aminoglycoside
resistance a
aph3-III-sat4A-ant6-Ia RT 033 A-B-CDT+ Human, n=1, pigs, n=3 and effluent, n=4






Human, n=16, calves, n=6, pigs, n=3, effluent, n=4 and 
food, n=1
RT 238 A-B-CDT+ Pigs, n=2 and calf, n=1 
RT 239 A-B-CDT+ Human, n=2 
RT 288 A-B-CDT+ Human, n=1 and calf, n=3 
RT 585 A-B-CDT+ Human, n=4 and foal, n=1 
RT 586 A-B-CDT+ Human, n=1 
QX 143 A-B-CDT+ Human, n=1 
QX 444 A-B-CDT+ Human, n=1 
QX 521 A-B-CDT+ Effluent, n=5 




gyrB (Gln160His, Ser366Val, 
Ser416Ala, Asp426Asn)
RT 033 A-B-CDT+ Human, n=1 
Glycopeptide resistance van B2 operon RT 033 A-B-CDT+ Calf, n=1 
Tetracycline resistance TetM RT 033 A-B-CDT+ Human, n=1 
397 aAll genomes positive for aminoglycoside resistance genes aph3-III and sat4A harboured a 
398 7269bp fragment of a resistance gene cassette from the ruminant facultative anaerobe 
399 Erysipelothrix rhusiopathiae (99% seq ID to KP339868.1). bResults obtained by manual 
400 curation of all A-B-CDT+ C. difficile genomes.
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Highlights
 Antimicrobial resistance (AMR) is common in C. difficile.
 Susceptibility testing generally focuses on toxigenic C. difficile strains.
 CDI due to non-toxigenic CDT producing strains (A-B-CDT+) is under-reported.
 AMR genes were identified in A-B-CDT+ C. difficile strains from various sources.
 These findings emphasize the importance of a One Health approach in combating AMR.
